Why is the Imugene share price sinking 13% this week?

a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.

The Imugene Limited (ASX: IMU) share price is down 13% since the closing bell this past Friday.

As covered by my Fool colleague James, the biotech company released a quarterly update yesterday.

The update revealed an operating cash outflow of $10.15 million. Research and development accounted for $8.5 million, and staff costs accounted for the bulk of the remaining expenditure.

However, the company remains in a strong financial position with a cash balance of $99.9 million.

In its statement, Imugene said: “The Company continues to monitor its expenditure carefully across all facets of the business, though this is expected to increase as clinical programs ramp up.”

Why is the Imugene share price struggling?

The performance of Imugene shares so far this week may be partly related to the update yesterday, and perhaps partly just a pullback after a very strong month.

As my Fool colleague Brooke reported last week, the Imugene share price has actually skyrocketed in recent times. At the time of reporting on 20 July, Imugene shares were up 77% over four weeks.

It’s not uncommon to see an ASX share pull back a little after a surge in value.

Some investors might choose to cash in some of their short-term profits, which we don’t generally recommend here at the Fool. We advocate the buy-and-hold strategy in most situations for ordinary ASX investors.

Imugene is an immuno-oncology company developing treatments to activate the immune systems of cancer patients.

So, like most biotech companies in development mode, the Imugene share price pretty much lives or dies from day to day based on the results of trials announced to the ASX, and other news relating to the company’s ongoing pursuit of medical advances.

What’s the latest news from Imugene?

Earlier this month, Imugene announced the appointment of executive director and clinical scientist Dr Sharon Yavrom.

Yavrom has almost 20 years of industry experience and has taken the lead role in multiple clinical trials for cancer treatments in the past.

The Imugene share price rose by 11% on the day of the news.

On 27 June, the company also reported the results of a phase 2 trial for the use of HER-Vaxx to treat advanced gastric cancer.

The trial showed a median overall survival of 13.9 months for patients treated with HER-Vaxx and chemotherapy. This compared to a survival rate of 8.3 months for patients who only received chemotherapy treatment.

ASX investors pushed the Imugene share price 41% higher on the day of this announcement.

The post Why is the Imugene share price sinking 13% this week? appeared first on The Motley Fool Australia.

Should you invest $1,000 in Imugene Limited right now?

Before you consider Imugene Limited, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Imugene Limited wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

See The 5 Stocks
*Returns as of July 7 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/fXdgsEb

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s